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planning scans to transfer relapse volume contours. Failures 
were classified as in-field (>95%), marginal (≥ 20% ≤ 95%) or 
out-field (< 20%) based on the percentage volume that 
received 95% of prescribed dose on visual assessment. 
Results: Overall, there were a total of 74 recurrences in 65 
patients. Nine of these 65 patients had both primary and 
nodal failure, 30 primary failure only, and 26 nodal failure 
only. A total of 39 failures were located within the primary 
tumour area and 35 failures in the neck nodes. The majority 
of loco-regional failures occurred in-field: 85% within PTV1 
and 8% within PTV2. Three failures (4%) were classified as 
marginal and only two (3%) arose out-field. After primary 
(chemo)IMRT, 43 failures occurred in the PTV1 and 5 were 
outside the PTV1 but inside PTV2. No out-field failures were 
observed. In the adjuvant setting, 5 patients had loco-
regional failures outside the PTV1. Dose–volume histogram 
analysis showed that all in-field failures received adequate 
dose coverage relative to the PTV. 
Conclusions: This data analysis suggests that most failures 
occur within the irradiated volume. Considering that 
incidence of geographical misses was low, future studies 
should be directed towards dose escalation in high-risk 
volumes. 
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Purpose/Objective: De-ESCALaTE-HPV is a prospective 
randomised phase III UK radiotherapy trial for low-risk Human 
Papilloma Virus positive oropharyngeal squamous cell 
carcinoma. In December 2013, the trial protocol changed to 
include both anatomical and volumetric outlining to reflect 
UK clinical practice. Centres were required to choose a 
method to delineate targets. The aim of this planning study 
was to quantify the dosimetric impact of these two outlining 
methods on normal tissues, particularly swallowing 
structures.  
Materials and Methods: Ten non-lateralised patients 
recruited to the trial were selected. Gross tumour volumes 
outlined by the recruiting investigators were used. For each 
patient, the high dose clinical target volume (CTV1) using 
anatomic and volumetric methods (Fig. 1), swallowing 
structures (Table 1) and organs at risk (OAR) for the trial 
were delineated by a single clinician. All structures were 
independently verified and modified as required for protocol 
compliance by a second clinician. A standardised class 
solution developed for delivering Volumetric Modulated Arc 
Therapy on CMS Monaco Treatment Planning System was used 
to plan all patients by a single planner. Swallowing structures 
were not used during optimisation. A treatment plan for each 
outlining method was generated for each patient. The 
volume of CTV1, mean dose and partial volume doses (V50, 
V60 and V70) to swallowing structures for each outlining 
method were recorded. Wilcoxon signed-rank test was used 
to compare the difference in doses. 
 
 
Figure 1 showing (a) Volumetric outlining (royal blue) which 
includes the primary Gross Tumour Volume (GTV – red) with a 
1-1.5cm geometric expansion in all directions in high dose 
CTV (CTV1-70Gy 35=); (b) Anatomical outlining (yellow) 
which includes the GTV, a 1-1.5cm margin and the whole 
oropharynx in CTV1; (c) Elective dose CTV (CTV2 – purple; 
56Gy 35=) is similar for both outlining protocols. 
 
Results: The target coverage and OAR doses were 
comparable for each patient between the two outlining 
methods. CTV1 volume was significantly larger using the 
anatomical method. The mean dose was significantly higher 
for all 3 pharyngeal constrictor muscles, supraglottic larynx 
and oral cavity with anatomical outlining. In addition, partial 
volume doses at all measured levels for superior and middle 
pharyngeal constrictor muscles were significantly larger for 
anatomical compared to volumetric method (Table 1).  
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Structure  
Outlining 
(A: 
Anatomical) 
(V: 
Volumetric) 
(p: p-value)  
Dosimetric parameter (Range)  
Mean 
(Gy)  
V70 (%) V60 (%) V50 (%) 
Superior 
Pharyngeal 
Constrictor  
A 70.1-71.0 53.8-82.1 98.8-100 All 100 
V 55.2-70.2 2.5-60.8 37.7-100 71.4-100 
p 0.005  0.005 0.005 0.012 
Middle 
Pharyngeal 
Constrictor 
A 69.5-71.5 54.2-90.1 97.6-100 All 100 
V  62.5-71.0 19.8-74.7 55.6-100 94.5-100 
p 0.007  0.005 0.012 0.043 
Inferior 
Pharyngeal 
Constrictor  
A 45.2-64.3 0-27.3 2-77.2 26.9-91.9 
V 44.4-65.8 0-33.1 0-83.3 20.8-92.8 
p 0.028 0.866 0.093 0.017 
Supraglottic 
Larynx  
A 54.6-69.7 26.7-59.9 53.1-100 57.3-100 
V 51.6-68.7 1.4-50.1 19.0-97.6 52.1-100 
p 0.005  0.005 0.007 0.012 
Oral Cavity  
A 41.8-56.3 0.3-10.8 7.0-44.5 22.1-66.9 
V 24.5-53.3 0-10.8 0-41.5 0.8-57.3 
p 0.012  0.093 0.012 0.012 
  
Volume (cm3)  
CTV1 
A 142.7-427.3  
V 70.7-402.2  
p 0.005  
Table 1: Mean dose Gray and partial volume doses as % 
 
Conclusions: This planning study demonstrated that the 
method of outlining influences the dose to normal structures. 
In particular, the dose to swallowing structures was 
significantly higher with anatomical outlining. This variation 
in delineating targets for treatment should be considered 
when assessing the final outcomes of this study. 
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Purpose/Objective: evaluating the clinical outcome of 
radiation dose escalation to 18FDG PET/CT positive tumor 
sub volumes using the Simultaneous Integrated Boost (SIB) 
IMRT technique by means of Helical Tomotherapy (HT), in 
locally advanced Oropharyngeal cancer patients. 
Materials and Methods: 38 patients treated between 2005 
and 2013 who underwent HT for squamocellular 
oropharyngeal stage III-IVB cancer were evaluated. HT was 
delivered with the SIB technique at different dose levels: 
69Gy (2.3 Gy/day) to the PET-positive volume (GTV-PET), 66 
Gy (2.2 Gy/day) to the clinical target volume for tumor and 
metastatic nodal stations, 54 Gy (1.8 Gy/day) to the clinical 
negative neck region concomitantly, in 30 fractions. 
Concurrent chemotherapy was given to 31 patients (cisplatin 
75-100 mg/m²/21 days for 23 patients, cisplatin 30-40 
mg/m²/week for 6 patients and Cetuximab for 2 patients) 
Metabolic indexes of primary tumour, including metabolic 
tumour volume (MTV), metabolic tumour volume thresholds 
40%, 50%, 60% (MTV-T-40%, MTV-T-50%, MTV-T-60%) and mean 
standardized uptake value (SUVmeanT) were also considered. 
Results: The median follow-up was 28 months (range: 3-109); 
all patients completed the treatment as scheduled. 
Temporary treatment interruption due to acute toxicity, 
mainly mucosae, was observed in 8 patients. The 2.5-year 
Overall Cancer specific (OS), Local disease-free Tumor (LTC) 
Local disease-free Nodal (LNC) and distant metastasis-free 
(DMFS) survivals were 88%, 83%, 88% and 77% respectively. 
Multivariate Cox regression analyses revealed that GTV-PET 
and GTV-T-PET are predictors for OS with a best-cut-off value 
equal to 30.9 cc (p=0.022) and 22.4 cc (p=0.029) 
respectively, while MTV-T-40%, MTV-T-60% and SUVmeanT 
are predictors for OS with a best-cut-off value equal to 21.3 
(p<0.0001), 13.3 (p<0.0001) and 9.2 (p=0.01) respectively 
Conclusions: The use of SIB-HT with dose escalation to 
18FDG-PET positive tumor sub-volumes is a feasible 
technique even with concurrent chemotherapy. Very 
promising 2.5-year loco-regional disease control rate are 
obtained. The results of the present study suggest that GTV-
PET has a predictive value for the SIB-HT outcome. These 
findings may constitute the basis for more personalized 
treatments.  
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Purpose/Objective: Dose to the oral mucosa and its 
contribution to acute mucositis is a dose/volume/outcome 
relationships recommended for investigation. Higher Dmean 
and Dmax would be supposed to produce more severe toxicity 
as such as other surveys have suggested. The aim of this 
study is to evaluate how different oral cavity (OC) contours in 
head-and-neck patients influence on treatment planning and, 
secondary, on the expected toxicity in head-and-neck IMRT. 
Materials and Methods: We analyzed the dose delivered to 
the oral cavity as organ at risk (OAR) designing three 
different contours in the same advanced head-and-neck 
cancer patient. Treatment was designed according to 
international recommendations utilising Intensity Modulated 
Radiotherapy (IMRT) technique with 7 fields and dynamic 
multileaf collimator, delivering 70 Gy to the Planning 
Treatment Volume (PTV). The Monaco treatment planning 
system with Monte Carlo algorithm was used. The 
Quantitative Analysis of Normal Tissue Effects in the Clinic 
(QUANTEC) report has not well-defined which structures 
should be included in the OC as organ at risk (OAR) and has 
not determined the constraints to apply. For this reason we 
defined three different contours including different 
structures (Tab. 1). Anterior OC included painful mucosa that 
can have a significant negative impact on quality of life and 
swallowing. Extended OC included anterior OC and other 
structures that inevitably are close to the PTV. Inner OC was 
a middle volume that includes the structures inside the 
gingiva. Oral cavity Dmean, Dmax, V50Gy, V45Gy, V40Gy, 
